Risk management to prevent hepatitis B reactivation by a hepatologist

DOI Web Site Web Site 4 References
  • Araki Masahiro
    Department of Gastroenterology, Ibaraki Prefectural Central Hospital, Ibaraki Cancer Center

Bibliographic Information

Other Title
  • 専門医の直接介入による内服薬などのB型肝炎再活性化予防のためのリスクマネジメント
  • センモンイ ノ チョクセツ カイニュウ ニ ヨル ナイフクヤク ナド ノ Bガタ カンエン サイカッセイカ ヨボウ ノ タメ ノ リスクマネジメント

Search this article

Abstract

<p>In 2009, "Guidelines for the prevention of hepatitis B virus (HBV) reactivation in patients receiving immunosuppressive therapy or chemotherapy" was published. Although HBV reactivation control has become well known, it is still not fully addressed. This hospital did not have sufficient support for oral medication, and there was an urgent need for action; so, efforts were made to prevent HBV reactivation through direct intervention by a specialist. A total of 2,348 patients received a new prescription during the 1-year period from April 2021 to March 2022. With the cooperation of the medical staff, screening tests were performed in nearly all cases where they were necessary, and medical safety concerns were reduced. Despite the need for considerable human effort, a high screening compliance rate should facilitate the transition to a multidisciplinary system without difficulty.</p>

Journal

  • Kanzo

    Kanzo 63 (10), 445-455, 2022-10-01

    The Japan Society of Hepatology

References(4)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top